DGI:Harnwegsinfektionen/Therapie/Kalkulierte Therapie: Difference between revisions

From Infektiopedia
imported>Brinkery
No edit summary
imported>Brinkery
(Der Seiteninhalt wurde durch einen anderen Text ersetzt: „==== Kalkulierte Therapie bei unkomplizierter Harnwegsinfektionen ==== Wenn aufgrund der diagnostischen Kriterien, die Diagnose eine…“)
Line 1: Line 1:
<span style="font-size:12.0pt;line-height:115%">Wenn aufgrund der diagnostischen Kriterien, die Diagnose einer unkomplizierten Harnwegsinfektion erfolgt ist, kann die antibiotische Therapie unabhängig von der Entscheidung zu einer ambulanten oder stationären Behandlung oral erfolgen. </span>
==== Kalkulierte Therapie bei unkomplizierter Harnwegsinfektionen ====
Wenn aufgrund der diagnostischen Kriterien, die Diagnose einer unkomplizierten Harnwegsinfektion erfolgt ist, kann die antibiotische Therapie unabhängig von der Entscheidung zu einer ambulanten oder stationären Behandlung oral erfolgen.  


<span style="font-size:12.0pt;line-height:115%">Die Entscheidung zur stationären Behandlung kann auch bei unkomplizierter Harnwegsinfektion aufgrund anderer Aspekte, wie z.B. Multimorbidität oder Sorge vor möglicher Incompliance erfolgen. </span>
Die Entscheidung zur stationären Behandlung kann auch bei unkomplizierter Harnwegsinfektion aufgrund anderer Aspekte, wie z.B. Multimorbidität oder Sorge vor möglicher Incompliance erfolgen.  
 
<span style="font-size:12.0pt;line-height:115%">Auch eine obere Harnwegsinfektion – Pyelonephritis – kann unkompliziert sein, wenn die entsprechenden Kriterien erfüllt sind. Eine Behandlung kann ambulant erfolgen, wenn die klinische Situation die Einnahme der Antibiotika und eine Flüssigkeitszufuhr zuverlässig ermöglicht.</span>


Auch eine obere Harnwegsinfektion – Pyelonephritis – kann unkompliziert sein, wenn die entsprechenden Kriterien erfüllt sind. Eine Behandlung kann ambulant erfolgen, wenn die klinische Situation die Einnahme der Antibiotika und eine Flüssigkeitszufuhr zuverlässig ermöglicht.
<br />
<br />


=====''<span style="font-size:12.0pt;line-height:115%">Kalkulierte Therapie bei unkomplizierter unterer Harnwegsinfektion</span>''=====
===== Kalkulierte Therapie bei unkomplizierter unterer Harnwegsinfektion =====
<span style="font-size:12.0pt;line-height:115%">Die aktuelle deutsche S3 Leitlinie zu unkomplizuerten Harnwegsinfektionen stellt eine ausführliche Auswahl an Antibiotika zur empirischen Therapie zur Verfügung. Aufgrund der individuellen Struktur der Apotheken je nach Krankenhaus und versorgender Abteilung, erfolgt die Auflistung innerhalb der Unterteilungen in alphabetischer Reihenfolge. Aufgrund der Tatsache, dass nicht alle First-Line Antibiotika in allen versorgenden Abteilungen gelistet sind, sind alle einsetzbaren Medikamente aufgeführt. Eine kleinere, lokale Auswahl kann unter Rücksichtigung der lokalen Resistenz erfolgen.</span>
Die aktuelle deutsche S3 Leitlinie zu unkomplizuerten Harnwegsinfektionen stellt eine ausführliche Auswahl an Antibiotika zur empirischen Therapie zur Verfügung. Aufgrund der individuellen Struktur der Apotheken je nach Krankenhaus und versorgender Abteilung, erfolgt die Auflistung innerhalb der Unterteilungen in alphabetischer Reihenfolge. Aufgrund der Tatsache, dass nicht alle First-Line Antibiotika in allen versorgenden Abteilungen gelistet sind, sind alle einsetzbaren Medikamente aufgeführt. Eine kleinere, lokale Auswahl kann unter Rücksichtigung der lokalen Resistenz erfolgen.


<span style="font-size:12.0pt;line-height:115%">Grundsätzlich deuten jedoch neue Studien darauf hin, dass Therapieregime mit einer längeren Applikationsdauer (3-5 Tage) eine höhere Eradikationsrate haben als Singleshot – Therapien. (Quelle s.u.) </span>
Grundsätzlich deuten jedoch neue Studien darauf hin, dass Therapieregime mit einer längeren Applikationsdauer (3-5 Tage) eine höhere Eradikationsrate haben als Singleshot – Therapien. (Quelle s.u.)  
{| class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" style="border-collapse:collapse;border:none;mso-border-alt:solid black .5pt;"
| style="width:60.35pt;border:solid black 1.0pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="80" valign="top" |'''Klinische Situation'''
| style="width:57.45pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="77" valign="top" |'''Präferenz'''
| style="width:86.45pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |'''Substanz'''
| style="width:61.4pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |'''Dosierung'''
| style="width:39.8pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |'''Dauer'''
| style="width:64.85pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |'''An-passungen'''
| style="width:82.5pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |'''Kommentar'''
|- style="mso-yfti-irow:1"
| rowspan="7" style="width:60.35pt;border:solid black 1.0pt;border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="80" valign="top" |Frauen, nicht-schwanger
| rowspan="5" style="width:57.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="77" valign="top" |First-Line
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Fosfomycin
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |3 g p.o <span style="mso-spacerun:yes"> </span> 0-0-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |1 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |Nach Möglichkeit  abends (längere Verweildauer in Blase)
|- style="mso-yfti-irow:2"
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Nitrofurantoin RT  (retard)
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |100 mg p.o.  1-0-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |5 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |
|- style="mso-yfti-irow:3"
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Nitrofurantoin
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |50 mg p.o.  1-1-1-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |5 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |
|- style="mso-yfti-irow:4"
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Nitroxolin
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |250 mg p.o.  1-1-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |5 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |
|- style="mso-yfti-irow:5"
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Pivmecillinam
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |400 mg p.o  1-1-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |3 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |
|- style="mso-yfti-irow:6"
| rowspan="2" style="width:57.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="77" valign="top" |alternativ
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Trimethoprim-  Sulfomethoxazol
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |960 mg p.o.  1-0-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |3 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| rowspan="2" style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |CAVE empirische  Gabe nur, wenn bekannt, dass E. coli-Resistenz <20%
|- style="mso-yfti-irow:7"
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Trimethoprim
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |200 mg p.o. 1-0-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |5 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
|- style="mso-yfti-irow:8"
| rowspan="3" style="width:60.35pt;border:solid black 1.0pt;border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="80" valign="top" |Frauen, schwanger
| rowspan="2" style="width:57.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="77" valign="top" |First-line
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Fosfomycin
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |3 g p.o <span style="mso-spacerun:yes"> </span> 0-0-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |1 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |Nach Möglichkeit abends (längere Verweildauer in Blase)
|- style="mso-yfti-irow:9"
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Pivmecillinam
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |400 mg p.o  1-1-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |5-7 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |
|- style="mso-yfti-irow:10"
| style="width:57.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="77" valign="top" |alternativ
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |<span style="color: black">Cefpodoxim-Proxetil </span>
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |100 mg p.o. 1-0-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |5-7 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |CAVE orale Cephalosporine können schwankende  Konzentrations-spiegel im Blut haben
|- style="mso-yfti-irow:11"
| rowspan="4" style="width:60.35pt;border:solid black 1.0pt;border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="80" valign="top" |Männer
| rowspan="3" style="width:57.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="77" valign="top" |First-line
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Nitrofurantoin
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |50 mg p.o.  1-1-1-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |7 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |
|- style="mso-yfti-irow:12"
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Nitrofurantoin RT (retard)
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |100 mg p.o.  1-0-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |7 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |
|- style="mso-yfti-irow:13"
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Pivmecillinam
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |400 mg p.o  1-1-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |7 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |
|- style="mso-yfti-irow:14;mso-yfti-lastrow:yes"
| style="width:57.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="77" valign="top" |alternativ
| style="width:86.45pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="115" valign="top" |Trimethoprim- Sulfomethoxazol
| style="width:61.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |960 mg p.o.  1-0-1
| style="width:39.8pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |3 d
| style="width:64.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="86" valign="top" |
| style="width:82.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="110" valign="top" |CAVE empirische Gabe nur, wenn bekannt, dass E. coli-Resistenz  <20%
|}
'''<span style="font-size:12.0pt;line-height:
115%">Auch wenn es zahlreiche Studien zur oralen Therapie mit Cephalosporinen gibt, sollte auf den primären Einsatz aufgrund der z.T. problematischen Bioverfügbarkeit mit schwankenden Serumspiegeln <span style="mso-spacerun:yes"> </span>verzichtet werden. </span>'''


<br />


=====''<span style="font-size:12.0pt;line-height:115%">Kalkulierte Therapie bei unkomplizierter oberer Harnwegsinfektion (Pyelonephritis)</span>''=====
{| class="wikitable"
{| class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" style="border-collapse:collapse;border:none;mso-border-alt:solid black .5pt;"
!Klinische Situation
| style="width:65.3pt;border:solid black 1.0pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="87" valign="top" |'''Klinische Situation'''
!Präferenz
| style="width:59.35pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="79" valign="top" |'''Präferenz'''
!Substanz
| style="width:72.4pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="97" valign="top" |'''Substanz'''
!Dosierung
| style="width:63.5pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="85" valign="top" |'''Dosierung'''
!Dauer
| style="width:41.0pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="55" valign="top" |'''Dauer'''
!Anpassungen
| style="width:81.25pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="108" valign="top" |'''Anpassungen'''
!Kommentar
| style="width:70.0pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="93" valign="top" |'''Kommentar'''
|-
|- style="mso-yfti-irow:1"
| rowspan="7" |Frauen, nicht-schwanger
| rowspan="2" style="width:65.3pt;border:solid black 1.0pt;border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="87" valign="top" |Frauen, nicht-schwanger, und
| rowspan="5" |First-Line
 
|Fosfomycin
Männer
|3 g p.o  0-0-1
| rowspan="2" style="width:59.35pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="79" valign="top" |First-Line
|1 d
| style="width:72.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="97" valign="top" |<span style="mso-comment-continuation:2">Ciprofloxacin</span><span style="mso-comment-continuation:
|
  2"><span class="MsoCommentReference"><span style="font-size:9.0pt">[[#%20msocom%201|[-1]]]</span></span></span> <span class="MsoCommentReference"><span style="font-size:9.0pt">[[#%20msocom%202|[FM2]]]</span></span>
|Nach Möglichkeit abends (längere Verweildauer in Blase)
| style="width:63.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="85" valign="top" |500-750 mg 1-0-1 p.o
|-
| style="width:41.0pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="55" valign="top" |7-10 d
|Nitrofurantoin RT (retard)
| rowspan="2" style="width:81.25pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="108" valign="top" |Nierenwerte
|100 mg p.o. 1-0-1
| rowspan="2" style="width:70.0pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="93" valign="top" |Wenn '''keine''' KI gegen FQ, sonst siehe  Therapie komplizierte Harnwegs-infektion
|5 d
|- style="mso-yfti-irow:2"
|
| style="width:72.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="97" valign="top" |Levofloxacin
|
| style="width:63.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="85" valign="top" |750 mg 1-0-0
|-
| style="width:41.0pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="55" valign="top" |5 d
|Nitrofurantoin
|- style="mso-yfti-irow:3;mso-yfti-lastrow:yes"
|50 mg p.o. 1-1-1-1
| style="width:65.3pt;border:solid black 1.0pt;border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="87" valign="top" |Frauen, schwanger
|5 d
| style="width:59.35pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="79" valign="top" |
|
| style="width:72.4pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="97" valign="top" |<span style="color: black">Cefpodoxim-Proxetil </span>
|
| style="width:63.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="85" valign="top" |100 mg p.o. 1-0-1
|-
| style="width:41.0pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="55" valign="top" |10 d
|Nitroxolin
| style="width:81.25pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="108" valign="top" |
|250 mg p.o. 1-1-1
| style="width:70.0pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="93" valign="top" |CAVE orale Cephalosporine können schwankende  Konzentra-tionsspiegel im Blut haben; wenn Allergie, siehe Therapie  komplizierte Harnwegs-infektion
|5 d
|
|
|-
|Pivmecillinam
|400 mg p.o 1-1-1
|3 d
|
|
|-
| rowspan="2" |alternativ
|Trimethoprim- Sulfomethoxazol
|960 mg p.o. 1-0-1
|3 d
|
|CAVE empirische Gabe nur, wenn bekannt, dass E. coli-Resistenz <20% (1; 7)
|-
|Trimethoprim
|200 mg p.o. 1-0-1
|5 d
|
|
|-
| rowspan="3" |Frauen, schwanger
| rowspan="2" |First-Line
|Fosfomycin
|3 g p.o  0-0-1
|1 d
|
|Nach Möglichkeit abends (längere Verweildauer in Blase)
|-
|Pivmecillinam
|400 mg p.o 1-1-1
|5 - 7 d
|
|
|-
|alternativ
|Cefpodoxim-Proxetil  
|100 mg p.o. 1-0-1
|5 - 7 d
|
|CAVE orale Cephalosporine können schwankende Konzentrations-spiegel im Blut haben
|-
| rowspan="4" |Männer
| rowspan="3" |First-Line
|Nitrofurantoin
|50 mg p.o. 1-1-1-1
|7 d
|
|
|-
|Nitrofurantoin RT (retard)
|100 mg p.o. 1-0-1
|7 d
|
|
|-
|
|400 mg p.o 1-1-1
|7 d
|
|
|-
|alternativ
|Trimethoprim- Sulfomethoxazol
|960 mg p.o. 1-0-1
|3 d
|
|CAVE empirische Gabe nur, wenn bekannt, dass E. coli-Resistenz <20% (1; 7)
|}
|}
'''<span style="font-size:12.0pt;line-height:
'''Auch wenn es zahlreiche Studien zur oralen Therapie mit Cephalosporinen gibt, sollte auf den primären Einsatz aufgrund der z.T. problematischen Bioverfügbarkeit mit schwankenden Serumspiegeln  verzichtet werden.'''
115%">Entscheidungshilfe symptomatische vs. antibiotische Therapie</span>'''
 
<span style="font-size:12.0pt;line-height:115%;mso-bidi-font-weight:
bold">Bei V.a. eine unkomplizierte untere Harnwegsinfektion kann die Indikation zur Antibiotikatherapie gestellt werden. Nachweislich wird dadurch die Symptomdauer verkürzt. Insbesondere im ambulanten Setting ist aber auch eine symptomatische Behandlungsmethode vertretbar. Daten und Empfehlungen zur symptomatischen Therapie bei Männern liegen nicht vor. In den durchgeführten Studien wurden nicht-schwangere, prämenopausale Frauen untersucht. Langzeitdaten konnten zeigen, dass bei reiner Zystitis auch bei Rezidiven nicht mit gravierenden Komplikationen zu rechnen ist. Auch ist die Spontanheilungsrate bei unkomplizierter Harnwegsinfektion ist mit 30-50% innerhalb einer Woche recht hoch <span style="color: #00B0F0">(1; 7). </span></span>
 
<span style="font-size:12.0pt;line-height:115%;mso-bidi-font-weight:
bold">Eine symptomatische Therapie ist mit Entzündungshemmern, wie z.B. Ibuprofen oder Paracetamol, möglich. Für unkomplizierte Harnwegsinfektionen bei geriatrischen Patientinnen ist diese Option nicht gegeben, da hierzu keine Daten vorliegen. </span>
 
<br />
<br />


=====<span style="text-decoration:none;text-underline:none">''Kalkulierte Therapie bei komplizierter Harnwegsinfektion''</span>=====
===== Kalkulierte Therapie bei unkomplizierter oberer Harnwegsinfektion (Pyelonephritis) =====
<span style="font-size:12.0pt;line-height:115%">Die Auswahl der Antibiotika ist zunächst unabhängig davon, ob eine untere oder obere Harnwegsinfektion vorliegt. Die Auswahl erfolgt anhand anderer Kriterien: der Einschätzung, ob eine ambulante Behandlung möglich ist, dem Vorliegen einer Sepsis oder dem Risiko für multiresistente Erreger als Auslöser der Infektion. </span>
 
<span style="font-size:12.0pt;line-height:115%">Patientinnen und Patienten mit komplizierter Harnwegsinfektion können sich entweder ambulant vorstellen oder sich bereits in stationärer in Behandlung befinden. </span>
 
<span style="font-size:12.0pt;line-height:115%">Für bereits stationär Behandelte gilt es ebenso, wie für die ambulant Vorstelligen, die Risikofaktoren für gram-negative Erreger abzufragen und die Checkliste VOR START der Antibiotikatherapie zu beachten. </span>
 
<span style="font-family:&quot;Arial&quot;,sans-serif;mso-fareast-font-family:Arial;
mso-fareast-language:EN-US">Bei Infektionen, welche 48 Std nach stationärer Aufnahme auftreten, handelt es sich um nosokomial erworbene Harnwegsinfektionen. </span>
 
<span style="font-family:&quot;Arial&quot;,sans-serif;
mso-fareast-font-family:Arial;mso-fareast-language:EN-US">Definitionsgemäß gehören auch die NOSOKOMIAL erworbenen <span style="mso-spacerun:yes"> </span>Harnwegsinfektionen zu den komplizierten Harnwegsinfektionen. Trotz gelegentlich abweichender Resistenz ambulant und stationär, können nosokomial erworbene Harnwegsinfektionen empirisch entsprechend der Empfehlungen in diesem Kapitel therapiert werden. </span>
 
<span style="font-family:&quot;Arial&quot;,sans-serif;
mso-fareast-font-family:Arial;mso-fareast-language:EN-US">Liegen KATHETER in den harnableitenden Wegen ein, werden Harnwegsinfektionen ebenfalls den komplizierten Harnwegsinfektionen zugeordnet. Bitte beachten Sie hierzu noch die Punkte unter „Die besondere klinische Situation: einliegende Katheter in den harnableitenden <span style="mso-comment-continuation:3">Wegen</span></span> <span style="font-family:&quot;Arial&quot;,sans-serif;mso-fareast-font-family:Arial;mso-fareast-language:
EN-US">“. </span>
 
'''<span style="font-size:12.0pt;line-height:
115%">Entscheidungshilfen stationäre vs. ambulante Versorgung des Patienten/der Patientin</span>'''
 
<span style="font-size:12.0pt;line-height:115%">Bei komplizierter Harnwegsinfektion gilt es ebenfalls die Entscheidung, ambulante oder stationäre Versorgung zu treffen. Die Entscheidung zur stationären Versorgung sollte individualisiert unter Beachtung bestimmter Risikofaktoren und Gegebenheiten und nicht ''allein'' ''aufgrund'' des V.a. oder der Diagnose einer komplizierten Harnwegsinfektion erfolgen. Die folgende Übersicht ist als Entscheidungshilfe gedacht.</span>
 
'''<span style="font-size:12.0pt;line-height:
115%">Stationäre Aufnahme zur weiteren Behandlung bei</span>'''
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>'''Sepsis''' </span>
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>'''septischem Schock'''</span>
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>'''Hinweisen für Obstruktion der harnableitenden Wege'''</span>
 
'''<span style="font-size:12.0pt;line-height:115%">Weitere Faktoren, die mit erhöhter Morbidität und Mortalität im Rahmen einer komplizierten Harnwegsinfektion eingehen gehen können, weswegen eine stationäre Aufnahme erfolgen sollte:</span>'''
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>persistierende Symptome: Schmerzen, Übelkeit und Erbrechen</span>
 
<span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span><span style="font-size:12.0pt;line-height:115%">Dehydrierung bei fehlender Möglichkeit zur oralen Hydrierung bzw. fehlende Stabilisierung nach initialer parenteraler</span> Hydrierung
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>Notwendigkeit einer intravenösen Antibiotikatherapie</span>
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>bekannte Demenz</span>
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>Zweifel an der Therapieadhärenz </span>
 
'''<span style="font-size:12.0pt;line-height:115%">Risikofaktoren für Infektion mit Gram-negativen, multiresistenten Erreger</span>'''
 
<span style="font-size:12.0pt;line-height:115%;font-family:&quot;Courier New&quot;;mso-fareast-font-family:
&quot;Courier New&quot;"><span style="mso-list:Ignore">o <span style="font:7.0pt &quot;Times New Roman&quot;"> </span></span></span><span style="font-size:12.0pt;line-height:115%">anamnestisch bekannte Besiedlung oder Z.n Infektion</span><span class="MsoCommentReference"><span style="font-size:9.0pt;line-height:115%">[[#%20msocom%204|[-4]]]<span style="mso-special-character:comment"> </span></span></span> <span style="font-size:12.0pt;line-height:115%">mit <span style="mso-spacerun:yes"> </span>Gram-negativen, multiresistenten Erregern (insbesondere bei Nachweis im Urin oder im Blut) oder resistenten gram positiven Erregern wie MRSA </span>
 
<span style="font-size:12.0pt;line-height:115%;font-family:&quot;Courier New&quot;;mso-fareast-font-family:
&quot;Courier New&quot;"><span style="mso-list:Ignore">o <span style="font:7.0pt &quot;Times New Roman&quot;"> </span></span></span><span style="font-size:12.0pt;line-height:115%">einliegende Katheter oder Stomata</span>
 
<span style="font-size:12.0pt;line-height:115%;font-family:&quot;Courier New&quot;;mso-fareast-font-family:
&quot;Courier New&quot;"><span style="mso-list:Ignore">o <span style="font:7.0pt &quot;Times New Roman&quot;"> </span></span></span><span style="font-size:12.0pt;line-height:115%">Pflegestufe 3</span>
 
<span style="font-size:12.0pt;line-height:115%;font-family:&quot;Courier New&quot;;mso-fareast-font-family:
&quot;Courier New&quot;"><span style="mso-list:Ignore">o <span style="font:7.0pt &quot;Times New Roman&quot;"> </span></span></span><span style="font-size:12.0pt;line-height:115%">Inkontinenz</span>
 
<span style="font-size:12.0pt;line-height:115%;font-family:&quot;Courier New&quot;;mso-fareast-font-family:
&quot;Courier New&quot;"><span style="mso-list:Ignore">o <span style="font:7.0pt &quot;Times New Roman&quot;"> </span></span></span><span style="font-size:12.0pt;line-height:115%">Bettlägerigkeit</span>
 
<span style="font-size:12.0pt;line-height:115%;font-family:&quot;Courier New&quot;;mso-fareast-font-family:
&quot;Courier New&quot;"><span style="mso-list:Ignore">o <span style="font:7.0pt &quot;Times New Roman&quot;"> </span></span></span><span style="font-size:12.0pt;line-height:115%">Krankenhausaufenthalt in den letzten 3 Monaten</span>
 
<span style="font-size:12.0pt;line-height:115%;
font-family:&quot;Courier New&quot;;mso-fareast-font-family:&quot;Courier New&quot;"><span style="mso-list:Ignore">o <span style="font:7.0pt &quot;Times New Roman&quot;"> </span></span></span><span style="font-size:12.0pt;line-height:115%">Einreise aus Ländern mit erhöhter MRE-Rate</span><span class="MsoCommentReference"><span style="font-size:9.0pt;line-height:115%">[[#%20msocom%205|[-5]]]</span></span> <span style="font-size:12.0pt;line-height:115%">: z.B. Asien, Mittelamerika etc.</span>
 
'''<span style="font-size:12.0pt;line-height:
115%">Checkliste VOR START der Antibiotikatherapie der komplizierten Harnwegsinfektion</span>'''
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">1. <span style="font:7.0pt &quot;Times New Roman&quot;">    </span></span>Uringewinnung zur Kultivierung</span>
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">2. <span style="font:7.0pt &quot;Times New Roman&quot;">    </span></span>Blutentnahme zur Kultivierung</span>
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">3. <span style="font:7.0pt &quot;Times New Roman&quot;">    </span></span>aktive Erinnerung daran, dass ein Antibiotikum NICHT EMPIRISCH eingesetzt werden sollte, wenn die LOKALE RESISTENZ für den erwarteten Erreger für dieses Antibiotikum >20% liegt! </span>
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">4. <span style="font:7.0pt &quot;Times New Roman&quot;">    </span></span>Wenn Risikofaktoren für gram-negative, multiresistente Erreger bestehen (Liste oben), die Tatsache bei der Wahl des Antibiotikums berücksichtigen </span>
 
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">5. <span style="font:7.0pt &quot;Times New Roman&quot;">   </span></span>Kontraindikation gegen Fluorchinolone prüfen</span>
 
<br />
<br />
=====''<span style="font-size:12.0pt;line-height:115%">Kalkulierte Therapie nach Entscheidung zur AMBULANTEN Versorgung</span>''=====
{| class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" style="border-collapse:collapse;border:none;mso-border-alt:solid black .5pt;"
| style="width:55.45pt;border:solid black 1.0pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="74" valign="top" |'''Klinische Situation'''
| style="width:56.5pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="75" valign="top" |'''Präferenz'''
| style="width:84.9pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="113" valign="top" |'''Substanz'''
| style="width:60.35pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="80" valign="top" |'''Dosierung'''
| style="width:39.2pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="52" valign="top" |'''Dauer'''
| style="width:89.9pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="120" valign="top" |'''Anpassungen'''
| style="width:66.5pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |'''Kommentar'''
|- style="mso-yfti-irow:1"
| rowspan="3" style="width:55.45pt;border:solid black 1.0pt;border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="74" valign="top" |Keine Risiko-faktoren für gram-negative, multi-resistente  Erreger
| style="width:56.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="75" valign="top" |First-Line
| style="width:84.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="113" valign="top" |Amoxicillin-Clavulansäure
| style="width:60.35pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="80" valign="top" |875/125 mg  1-0-1 p.o.
| style="width:39.2pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="52" valign="top" |5-10 d
| style="width:89.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="120" valign="top" |Leberwerte
| style="width:66.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |
|- style="mso-yfti-irow:2"
| rowspan="2" style="width:56.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="75" valign="top" |alternativ
| style="width:84.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="113" valign="top" |<span style="mso-comment-continuation:7">Ciprofloxacin<span class="MsoCommentReference"><span style="font-size:9.0pt">[[#%20msocom%206|[-6]]]</span></span></span> <span class="MsoCommentReference"><span style="font-size:9.0pt">[[#%20msocom%207|[FM7]]]</span></span>
| style="width:60.35pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="80" valign="top" |500 mg 1-0-1  p.o
| style="width:39.2pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="52" valign="top" |5-10 d
| style="width:89.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="120" valign="top" |Nierenwerte
| rowspan="2" style="width:66.5pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |Bei Penicillin-allergie
|- style="mso-yfti-irow:3;mso-yfti-lastrow:yes"
| style="width:84.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="113" valign="top" |Trimethoprim-Sulfomethoxazol
| style="width:60.35pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="80" valign="top" |960 mg 1-0-1 p.o.
| style="width:39.2pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="52" valign="top" |5-10 d
| style="width:89.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="120" valign="top" |Nierenwerte
|}
'''<span style="font-size:12.0pt;
line-height:115%">Besteht grundsätzlich eine ambulante Versorgungsmöglichkeit, liegen aber gleichzeitig Risikofaktoren für gram-negative multiresistente Erreger vor, dann:</span>'''
<span style="font-size:12.0pt;line-height:
115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span></span>'''<span style="font-size:12.0pt;line-height:115%">Empfehlung stationäre Aufnahme</span>'''
<span style="font-size:12.0pt;
line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span></span>'''<span style="font-size:12.0pt;line-height:115%">Start intravenöse empirischen AB-Therapie entsprechend der Empfehlungen in der folgenden Tabelle</span>'''
<br />
=====''<span style="font-size:12.0pt;line-height:115%">Kalkulierte Therapie bei STATIONÄRER Versorgung </span>''=====
<span style="font-size:12.0pt;line-height:115%">Bei der Auswahl der Antibiotika sind 3 Aspekte zu beachten </span>
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>(V.a.) Sepsis oder septischer Schock</span>
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>(V.a.) Obstruktion der harnableitenden Wege</span>
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>Risikofaktoren (RF) für gram-negative Erreger (gn MRE): siehe Auslistung oben</span>
{| class="MsoTableGrid" border="1" cellspacing="0" cellpadding="0" style="border-collapse:collapse;border:none;mso-border-alt:solid black .5pt;"
| style="width:65.75pt;border:solid black 1.0pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="88" valign="top" |'''Klinische Situation'''
| style="width:57.25pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="76" valign="top" |'''Präferenz'''
| style="width:66.9pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |'''Substanz'''
| style="width:61.2pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |'''Dosierung'''
| style="width:39.7pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |'''Dauer- <span style="font-size:8.0pt;line-height:
  115%">Bitte Kommentar beachten in Anschluss an die Tabelle.</span>'''
| style="width:78.15pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="104" valign="top" |'''Anpassungen'''
| style="width:83.85pt;border:solid black 1.0pt;border-left:none;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="112" valign="top" |'''Kommentar'''
|- style="mso-yfti-irow:1"
| rowspan="2" style="width:65.75pt;border:solid black 1.0pt;border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="88" valign="top" |nicht septisch, KEIN V.a. Obstruktion, KEINE RF für gn MRE
| style="width:57.25pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="76" valign="top" |First-Line
| style="width:66.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |<span style="mso-comment-continuation:9">Ceftriaxon</span><span style="mso-comment-continuation:
  9"><span class="MsoCommentReference"><span style="font-size:9.0pt">[[#%20msocom%208|[-8]]]</span></span></span> <span class="MsoCommentReference"><span style="font-size:9.0pt">[[#%20msocom%209|[FM9]]]<span style="mso-special-character:
  comment"> </span></span></span><span style="mso-ansi-language:EN-US"> </span>
| style="width:61.2pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |2 g i.v. <span style="mso-spacerun:yes"> </span>  1-0-0
| style="width:39.7pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |5-14d<span class="MsoCommentReference"><span style="font-size:9.0pt">[[#%20msocom%2010|[-10]]]</span></span>
| style="width:78.15pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="104" valign="top" |
| style="width:83.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="112" valign="top" |
|- style="mso-yfti-irow:2"
| style="width:57.25pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="76" valign="top" |alternativ
| style="width:66.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |Piperacillin-Tazobactam
| style="width:61.2pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |4,5 g i.v. 1-1-1-1
| style="width:39.7pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |5-14d
| style="width:78.15pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="104" valign="top" |
| style="width:83.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="112" valign="top" |Wenn KI gegen  Cephalosporine
|- style="mso-yfti-irow:3"
| rowspan="2" style="width:65.75pt;border:solid black 1.0pt;border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="88" valign="top" |septisch, KEIN V.<span style="mso-comment-continuation:12">a</span><span style="mso-comment-continuation:
  12"><span class="MsoCommentReference"><span style="font-size:9.0pt">[[#%20msocom%2011|[-11]]]</span></span></span> <span class="MsoCommentReference"><span style="font-size:9.0pt">[[#%20msocom%2012|[FM12]]]</span></span> .  Obstruktion, KEINE RF für gn MRE
| style="width:57.25pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="76" valign="top" |First-Line
| style="width:66.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |Piperacillin-Tazobactam
| style="width:61.2pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |4,5 g i.v. 1-1-1-1
| style="width:39.7pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |7-14 d
| style="width:78.15pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="104" valign="top" |
| style="width:83.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="112" valign="top" |
|- style="mso-yfti-irow:4"
| style="width:57.25pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="76" valign="top" |alternativ
| style="width:66.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |Meropenem
| style="width:61.2pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |1 g i.v.
1-1-1
| style="width:39.7pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |7-14d
| style="width:78.15pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="104" valign="top" |
| style="width:83.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="112" valign="top" |Penicillinallergie mit Ana-phylaxie
|- style="mso-yfti-irow:5"
| rowspan="2" style="width:65.75pt;border:solid black 1.0pt;border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="88" valign="top" |septisch oder  nicht septisch, kein V.a. Obstruktion, RF für gn MRE
| style="width:57.25pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="76" valign="top" |First-Line
| style="width:66.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |Meropenem
| style="width:61.2pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |1 g i.v.
1-1-1
| style="width:39.7pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |7-14d
| style="width:78.15pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="104" valign="top" |
| style="width:83.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="112" valign="top" |
|- style="mso-yfti-irow:6"
| style="width:57.25pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="76" valign="top" |alternativ
| style="width:66.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |'''***''' ggf. individuelle  Therapie mit Reserve- Antibiotika
| style="width:61.2pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |
| style="width:39.7pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |
| style="width:78.15pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="104" valign="top" |
| style="width:83.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="112" valign="top" |Bei KI gegen Carbapeneme
'''***CAVE unten  beachten'''
|- style="mso-yfti-irow:7"
| rowspan="2" style="width:65.75pt;border:solid black 1.0pt;border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="88" valign="top" |septisch oder  nicht septisch, V.a. Obstruktion, unabhängig von RF für gn MRE
| style="width:57.25pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="76" valign="top" |First-Line
| style="width:66.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |Meropenem
PLUS
Vancomycin
| style="width:61.2pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |1 g i.v.
1-1-1
15-20  mg/kgKG
i.v. 1-0-1 
| style="width:39.7pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |7-14d
| style="width:78.15pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="104" valign="top" |
| style="width:83.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="112" valign="top" |
|- style="mso-yfti-irow:8"
| style="width:57.25pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="76" valign="top" |alternativ
| style="width:66.9pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="89" valign="top" |'''***''' ggf. individuelle  Therapie mit Reserve- Antibiotika
| style="width:61.2pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="82" valign="top" |
| style="width:39.7pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="53" valign="top" |
| style="width:78.15pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="104" valign="top" |
| style="width:83.85pt;border-top:none;border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;mso-border-top-alt:solid black .5pt;mso-border-left-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="112" valign="top" |Bei KI gegen Carbapeneme oder Vancomycin
'''***CAVE unten  beachten'''!
|- style="mso-yfti-irow:9;mso-yfti-lastrow:yes"
| colspan="7" style="width:452.8pt;border:solid black 1.0pt;border-top:none;mso-border-top-alt:solid black .5pt;mso-border-alt:solid black .5pt;padding:0cm 5.4pt 0cm 5.4pt;" width="604" valign="top" |'''<span style="font-size:13.0pt;line-height:115%">***CAVE: Vor Therapie mit  Reserve-Antibiotika infektiologisches Konsil empfohlen und/oder Rücksprache mit  der Apotheke bzw. Mikrobiologie</span>'''
|}
'''<span style="font-size:
12.0pt;line-height:115%">Bitte beachten Kommentar Therapiedauer:</span>''' <span style="font-size:12.0pt;line-height:115%">Der Range bei der Therapiedauer ergibt sich aus den verschiedenen klinischen Situationen der Pat. Lassen sich eine Pyelonephritis und/oder Urosepsis feststellen, dann ist der Range der empfohlenen Therapiedauer 7-14 d. Bei der Entscheidung für eine individuelle Therapiedauer gibt es unterstützende Faktoren.</span>
<span style="font-size:12.0pt;line-height:115%">Eine längere Therapiedauer entspricht nicht grundsätzlich einer besseren Behandlung oder einem besseren Rezidivschutz. Eine kürzere Therapiedauer sollte '''immer''', wenn die Möglichkeit besteht, gewählt werden. Es konnte gezeigt werden, dass für bestimmte klinische Situationen, die kürzere Therapiedauer der längeren nicht unterlegen ist. Eine kurze Therapiedauer kann gewählt werden, wenn: </span>
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>die Pat. spätestens 2-3 d nach AB-Start entfiebern und/oder Symptome und/oder Entzündungswerte rückläufig sind</span>
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>bei Vorliegen einer Obstruktion diese beseitigt werden kann</span>
<span style="font-size:12.0pt;line-height:115%"><span style="mso-list:Ignore">- <span style="font:7.0pt &quot;Times New Roman&quot;">      </span></span>einliegendes Fremdmaterial zeitnah nach Therapiestart gewechselt oder entfernt werden kann</span>
<span style="font-size:12.0pt;line-height:115%">Bei Pseudomonaden als auslösende Erreger findet sich in der Literatur häufiger der Hinweis, dass eine längere Therapiedauer von 10-14 d notwendig ist, da ein verzögertes Ansprechen auf die Antibiotikatherapie beschrieben ist.</span>
'''<span style="font-size:
12.0pt;line-height:115%">Bei Vorliegen der mikrobiologischen Befunde: Empirische Antibiotikatherapie nach spätestens 72 h reevaluieren und anpassen: Therapiedauer evaluieren, deeskalieren, so fokussiert wie möglich behandeln, Oralisierungsoptionen prüfen.</span>'''
----<br />

Revision as of 08:45, 9 August 2022

Kalkulierte Therapie bei unkomplizierter Harnwegsinfektionen

Wenn aufgrund der diagnostischen Kriterien, die Diagnose einer unkomplizierten Harnwegsinfektion erfolgt ist, kann die antibiotische Therapie unabhängig von der Entscheidung zu einer ambulanten oder stationären Behandlung oral erfolgen.

Die Entscheidung zur stationären Behandlung kann auch bei unkomplizierter Harnwegsinfektion aufgrund anderer Aspekte, wie z.B. Multimorbidität oder Sorge vor möglicher Incompliance erfolgen.

Auch eine obere Harnwegsinfektion – Pyelonephritis – kann unkompliziert sein, wenn die entsprechenden Kriterien erfüllt sind. Eine Behandlung kann ambulant erfolgen, wenn die klinische Situation die Einnahme der Antibiotika und eine Flüssigkeitszufuhr zuverlässig ermöglicht.

Kalkulierte Therapie bei unkomplizierter unterer Harnwegsinfektion

Die aktuelle deutsche S3 Leitlinie zu unkomplizuerten Harnwegsinfektionen stellt eine ausführliche Auswahl an Antibiotika zur empirischen Therapie zur Verfügung. Aufgrund der individuellen Struktur der Apotheken je nach Krankenhaus und versorgender Abteilung, erfolgt die Auflistung innerhalb der Unterteilungen in alphabetischer Reihenfolge. Aufgrund der Tatsache, dass nicht alle First-Line Antibiotika in allen versorgenden Abteilungen gelistet sind, sind alle einsetzbaren Medikamente aufgeführt. Eine kleinere, lokale Auswahl kann unter Rücksichtigung der lokalen Resistenz erfolgen.

Grundsätzlich deuten jedoch neue Studien darauf hin, dass Therapieregime mit einer längeren Applikationsdauer (3-5 Tage) eine höhere Eradikationsrate haben als Singleshot – Therapien. (Quelle s.u.)


Klinische Situation Präferenz Substanz Dosierung Dauer Anpassungen Kommentar
Frauen, nicht-schwanger First-Line Fosfomycin 3 g p.o 0-0-1 1 d Nach Möglichkeit abends (längere Verweildauer in Blase)
Nitrofurantoin RT (retard) 100 mg p.o. 1-0-1 5 d
Nitrofurantoin 50 mg p.o. 1-1-1-1 5 d
Nitroxolin 250 mg p.o. 1-1-1 5 d
Pivmecillinam 400 mg p.o 1-1-1 3 d
alternativ Trimethoprim- Sulfomethoxazol 960 mg p.o. 1-0-1 3 d CAVE empirische Gabe nur, wenn bekannt, dass E. coli-Resistenz <20% (1; 7)
Trimethoprim 200 mg p.o. 1-0-1 5 d
Frauen, schwanger First-Line Fosfomycin 3 g p.o 0-0-1 1 d Nach Möglichkeit abends (längere Verweildauer in Blase)
Pivmecillinam 400 mg p.o 1-1-1 5 - 7 d
alternativ Cefpodoxim-Proxetil 100 mg p.o. 1-0-1 5 - 7 d CAVE orale Cephalosporine können schwankende Konzentrations-spiegel im Blut haben
Männer First-Line Nitrofurantoin 50 mg p.o. 1-1-1-1 7 d
Nitrofurantoin RT (retard) 100 mg p.o. 1-0-1 7 d
400 mg p.o 1-1-1 7 d
alternativ Trimethoprim- Sulfomethoxazol 960 mg p.o. 1-0-1 3 d CAVE empirische Gabe nur, wenn bekannt, dass E. coli-Resistenz <20% (1; 7)

Auch wenn es zahlreiche Studien zur oralen Therapie mit Cephalosporinen gibt, sollte auf den primären Einsatz aufgrund der z.T. problematischen Bioverfügbarkeit mit schwankenden Serumspiegeln verzichtet werden.

Kalkulierte Therapie bei unkomplizierter oberer Harnwegsinfektion (Pyelonephritis)